Results 291 to 300 of about 168,682 (384)

Radiotherapy Upregulates the Expression of Membrane-Bound Negative Complement Regulator Proteins on Tumor Cells and Limits Complement-Mediated Tumor Cell Lysis. [PDF]

Cancers (Basel)
Liang Y, Mai L, Schneeweiss JM, Lopez Perez R, Kirschfink M, Huber PE.   +5 more
europepmc   +1 more source

ALK+, CD30−, CD20− Large B-Cell Lymphoma Containing Anaplastic Lymphoma Kinase (ALK) Fused to Clathrin Heavy Chain Gene (CLTC)

, 2003
Norio Chikatsu, Hiroshi Kojima, Kazumi Suzukawa, Atsushi Shinagawa, Toshiro Nagasawa, Hiroaki Ozawa, Yoriko Yamashita, Naoyoshi Mori   +7 more
openalex   +1 more source

Predictive factors and nomogram for the risk of cytokine release syndrome with anti-CD3 × CD20 bispecific antibodies for Chinese patients. [PDF]

Cancer Immunol Immunother
Sun P, Chen C, Zhao BT, Zhang BY, Yang H, Wang Y, Xu F, Huang KM, Liu YT, Ouyang MS, Huang JJ, Liu PP, Guo Y, Li ZM.   +13 more
europepmc   +1 more source

Expression of IL‐4 Receptor Alpha in Ectopic Lymphoid Tissue in Chronic Rhinosinusitis

Allergy, EarlyView.
Kengo Kanai, Hiroyuki Kusano, Aiko Oka, Marie Yamada, Ryo Takagi, Isao Suzaki, Kojiro Hirano, Junqin Bai, Takayuki Shiomi, Mitsuhiro Okano   +9 more
wiley   +1 more source

Dysregulation of the endosomal sorting complex III is linked to neurodegeneration in progressive multiple sclerosis

Brain Pathology, EarlyView.
This study shows that components of the ESCRT‐III membrane repair machinery, VPS4B and CHMP2A, are dysregulated in progressive MS and are associated with higher neurodegeneration and inflammation. This might lead to improper function of the complex to inhibit the final stages of necroptosis activation and thus impede neuronal cell death.
Carmen Picon, Robertas Aleksynas, Marcelina Wojewska, Francesco de Virgiliis, Doron Merkler, Richard Reynolds   +5 more
wiley   +1 more source

Bright-Field Multiplex Immunohistochemistry in Swine PCV2 and PRRSV Lymphadenopathies. [PDF]

Animals (Basel)
D'Annunzio G, Muscatello LV, Tugnoli C, Pesaro S, Luppi A, Fiorentino M, Franceschini T, Grillini A, Rugna G, Sarli G, Mandrioli L.   +10 more
europepmc   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Secondary Organising Pneumonia Among Immunocompromised Multiple Sclerosis Patients Treated With Ocrelizumab Following COVID-19 Infection: Two Case Reports With Literature Review. [PDF]

Respirol Case Rep
Aljarod TM, Morehead RS.
europepmc   +1 more source

Artificial intelligence streamlines scientific discovery of drug–target interactions

British Journal of Pharmacology, EarlyView.
Abstract Drug discovery is a complicated process through which new therapeutics are identified to prevent and treat specific diseases. Identification of drug–target interactions (DTIs) stands as a pivotal aspect within the realm of drug discovery and development. The traditional process of drug discovery, especially identification of DTIs, is marked by
Yuxin Yang, Feixiong Cheng
wiley   +1 more source

B cell-extrinsic and intrinsic factors linked to early immune repletion after anti-CD20 therapy in patients with multiple sclerosis of African ancestry. [PDF]

Front Immunol
Silverman GJ, Amarnani AN, Armini AA, Kim A, Kopinsky H, Fenyo D, Kister I.   +6 more
europepmc   +1 more source